Peregrine's (PPHM) Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
Up)
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that fusion proteins combining the anti-cancer cytokines alpha interferon and interleukin 2 (IL-2) with 2aG4, a bavituximab equivalent, demonstrated potent anti-cancer activity in preclinical models of B-cell lymphoma and melanoma.
In these studies, the antibody-cytokine fusion proteins generated a robust anti-tumor response without any observable toxicity. These immunocytokine fusion proteins incorporating antibodies that target the blood vessels of tumors are new preclinical candidates under Peregrine's proprietary Vascular Targeting Agent (VTA) technology platform.
The resulting immunocytokine fusion proteins were capable of selectively targeting tumor blood vessels and displayed potent anti-cancer effects in a number of tumor models without causing any observable toxicity. The studies also showed that different forms of the VTAs could be combined, and that the combination of 2aG4-IL-2 with 2aG4-alpha interferon was significantly more effective in inhibiting tumor growth than either agent alone. In a preclinical model of B-cell lymphoma, tumor growth was inhibited by 85% in the combination-treated group compared with 60% and 65% in animals treated with either 2aG4-IL-2 or 2aG4-alpha interferon, respectively.
In these studies, the antibody-cytokine fusion proteins generated a robust anti-tumor response without any observable toxicity. These immunocytokine fusion proteins incorporating antibodies that target the blood vessels of tumors are new preclinical candidates under Peregrine's proprietary Vascular Targeting Agent (VTA) technology platform.
The resulting immunocytokine fusion proteins were capable of selectively targeting tumor blood vessels and displayed potent anti-cancer effects in a number of tumor models without causing any observable toxicity. The studies also showed that different forms of the VTAs could be combined, and that the combination of 2aG4-IL-2 with 2aG4-alpha interferon was significantly more effective in inhibiting tumor growth than either agent alone. In a preclinical model of B-cell lymphoma, tumor growth was inhibited by 85% in the combination-treated group compared with 60% and 65% in animals treated with either 2aG4-IL-2 or 2aG4-alpha interferon, respectively.
You May Also Be Interested In
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
- Bayer, Onyx Pharma (ONXX) Say Nexavar Missed Primary Endpoint in Phase 3
- Medivation (MDVN) Submits NDA for Enzalutamide to U.S. FDA
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
